Phase 1 Trial of Cudetaxestat as IPF Combo in Healthy Adults Opens

Phase 1 Trial of Cudetaxestat as IPF Combo in Healthy Adults Opens

309716

Phase 1 Trial of Cudetaxestat as IPF Combo in Healthy Adults Opens

A Phase 1 trial assessing how cudetaxestat, an investigational treatment for idiopathic pulmonary fibrosis (IPF), interacts with two approved IPF treatments, Ofev (nintedanib) and Esbriet (pirfenidone), is now enrolling healthy volunteers, Blade Therapeutics, the therapy’s developer, announced. The trial (NCT04939467) is aiming to enroll 86 healthy adults, ages 18 to 55. Following an overnight fast, participants will receive the oral combination therapies in a fixed sequence: either 150 mg of Boehringer Ingelheim’s Ofev twice daily or 267 mg of Genentech’s Esbriet…

You must be logged in to read/download the full post.